Pharmacokinetics and pharmacodynamics of insulin detemir (Levemir®) and insulin glargine (Lantus®) after subcutaneous injection of increasing doses into morbidly obese type 2 diabetic subjects

Not Applicable

Completed

• Conditions: Diabetes, obesity; Nutritional, Metabolic, Endocrine; Diabetes and obesity

• Registration Number: ISRCTN57547229
• Lead Sponsor: niversity Hospital Basel (Switzerland)

Brief Summary

2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30114246 [added 01/02/2019]

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-05-09
• Study Completion: 2007-04-30
• Last Update Posted: 4 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. History of type 2 diabetes mellitus
2. Age 18-65 years
3. Body mass index >35 kg/m^2
4. HbA1c <10%

Exclusion Criteria

1. Any severely active hepatic, cardiovascular, pulmonary, renal, neurological, musculoskeletal, hematological or endocrine disease
2. Pregnant or breast feeding women
3. Woman of childbearing potential not using a reliable method of birth control such as oral contraceptives or an intrauterine device (IUD)
4. Subjects refusing or unable to give written informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified